TIMPs and MMPs expression in CSF from patients with TSP/HAM

Life Sciences

Volumn 72, Issue 25, 2003, Pages 2863-2876

  Kettlun, Ana M ^a   Cartier, Luis ^b   García, Lorena ^a   Collados, Lucía ^a   Vásquez, Felipe ^a   Ramírez, Eugenio ^c   Valenzuela, M Antonieta ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

Author keywords

Cerebrospinal fluid; MMPs; Neurological inflammatory diseases; TIMPs; Tropical spastic paraparesis; TSP HAM

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; INFLAMMATORY DISEASE; MALE; NEUROPATHOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SPINAL CORD DISEASE; UPREGULATION; ZYMOGRAPHY;

EID: 0344406896     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00146-2     Document Type: Article

References (40)

1. Gessain A., Barin F., Vernant J.C., Gout O., Maurs L., Calender A., de The G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 2:1985;407-410.
2. Cartier L., Cea J.G., Vergara C., Araya F., Born P. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. Journal of Neuropathology and Experimental Neurology. 56(4):1997;403-413.
3. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of CNS. Trends in Neuroscience. 21(2):1998;75-80.
4. Lukes A., Mun-Bryce S., Lukes M., Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Molecular Neurobiology. 19(3):1999;267-284.
5. Wright J.W., Kramár E.A., Meigham S.E., Harding J.W. Extracellular matrix molecules, long-term potentiation, memory consolidation and the brain angiotensin system. Peptides. 23(1):2002;221-246.
6. Nagase H., Woessner J.F. Matrix metalloproteinases. Journal of Biological Chemistry. 274(31):1999;21491-21494.
7. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C., Adams S.E., Gearing A.J. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Journal of Neuroimmunology. 72(2):1997;155-161.
8. VanSaun M., Werle M.J. Matrix metalloproteinase-3 removes agrin from synaptic basal lamina. Journal of Neurobiology. 43(3):2000;140-149.
9. Imai K., Yokohama Y., Nakanishi I., Ohuchi E., Fujii Y., Nakai N., Okada Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Journal of Biological Chemistry. 270(12):1995;6691-6697.
10. Gómez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. European Journal of Cell Biology. 74(2):1997;111-122.
11. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta. 1477(1-2):2000;267-283.
12. Connant K., McArthur J.C., Griffin D.E., Sjulson L., Wahl L.M., Irani D.N. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Annals of Neurology. 46(3):1999;391-398.
13. Liuzzi G.M., Mastroianni C.M., Santacroce M.P., Fanelli M., D'Agostino C., Vullo V., Riccio P. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. Journal of Neurovirology. 6(2):2000;156-183.
14. Kieseier B.C., Paul R., Koedel U., Seifert T., Clements J.M., Gearing A.J., Pfister H.W., Hartung H.P. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain. 122(Pt 8):1999;1579-1587.
15. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. Journal of Neuroimmunology. 84(2):1998;143-150.
16. Leppert D., Leib S.L., Grygar C., Miller K.M., Schaad U.B., Hollander G.A. Matrix metalloproteinase (MMP-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis:association with blood-brain barrier damage and neurogical sequelae. Clinical Infections Diseases. 31(1):2000;80-84.
17. Matsuura E., Umehara F., Hashiguchi T., Fujimoto N., Okada Y., Osame M. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. Journal of Neurological Sciences. 173(1):2000;45-52.
18. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Valk P., De Groot C.J.A. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathologica. 94(6):1997;590-598.
19. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathology and Applied Neurobiology. 23(5):1997;406-415.
20. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121(Pt 12):1998;2327-2334.
21. Bar-Or A., Oliveira E.M.L., Anderson D.E., Hafler D.A. Molecular pathogenesis of multiple sclerosis. Journal of Neuroimmunology. 100(1-2):1999;252-259.
22. Mandler R.N., Dencoff J.D., Midani F., Ford C.C., Ahmed W., Rosenberg G.A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain. 124(Pt3):2001;493-498.
23. Kieseier B.C., Clements J.M., Pischel G.M.A., Wells M.A., Miller K., Gearing A.J.H., Hartung H.P. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré Syndrome. Annals of Neurology. 43(4):1998;427-434.
24. Valenzuela M.A., Cartier L., Collados L., Kettlun A.M., Araya F., Concha C., Flores L., Wolf M.E., Mosnaim A.D. Gelatinase activity of matrix metalloproteinase in the cerebrospinal fluid of various patients populations. Research Communications in Molecular Pathology and Pharmacology. 104(1):1999;42-52.
25. Giraudon P., Buart S., Bernard A., Thomasset N., Belin M.F. Extracellular matrix-remodeling metalloproteinases and infections of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Progress in Neurobiology. 49(2):1996;169-184.
26. Umehara F., Okada Y.O., Fujimoto N., Abe M., Izumo S., Osame M. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-I-associated myelopathy. Journal of Neuropathology and Experimental Neurology. 57(9):1998;839-849.
27. Giraudon P., Vernant J.C., Confavreux C., Belin M.F., Desgranges C. Matrix metalloproteinase-9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology. 50(6):1998;p1920.
28. Lezin A., Buart S., Smadja D., Akaoka H., Bourdonne O., Perret-Liaudet A., Cesaire R., Belin M.F., Giraudon P. Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. Aids Research and Human Retroviruses. 16(10):2000;965-972.
29. Valenzuela M.A., Collados L., Kettlun A.M., González F., Cartier L. Increased activity of metalloproteinases and their inhibitors in cerebrospinal fluid of patients with tropical spatic paraparesis. Revista Médica de Chile. 128(6):2000;585-592.
30. Giraudon P., Szymocha R., Buart S., Bernard A., Cartier L., Belin M.F., Akaoka H. T Lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogeneous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. Journal of Immunology. 164(5):2000;2718-2727.
31. Galeno H., Ramírez E., Mora M., Ojeda M., Cartier L. Anti-HTLV-I antibody titers in seropositive infected individuals. Revista Médica de Chile. 122(9):1994;1004-1007.
32. Ramírez E., Cartier L., Ríos M., Fernández J. Defective human T-cell lymphotropic virus type I (HTLV-I) provirus in 10 Chilean seronegative patients with tropical spastic paraparesis or HTLV-I-associated myelopathy. Journal of Clinical Microbiology. 36(6):1998;1811-1813.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
34. Miyazaki K., Hasegawa M., Funahashi K., Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature. 362(6423):1993;839-841.
35. Oliver G.W., Leferson J.D., Stetler-Stevenson W.G., Kleiner D.E. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Analytical Biochemistry. 244(1):1997;161-166.
36. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M., Pfister H.W. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Annals of Neurology. 44(4):1998;592-600.
37. Gottschall P.E., Deb S. Regulation of matrix metalloproteinases expression in astrocytes, microglia and neurons. Neuroimmunomodulation. 3(2-3):1996;69-75.
38. Mori N., Sato H., Hayashibara T., Senba M., Hayashi T., Yamada Y., Kamihira S., Ikeda S., Yamasaki Y., Morikawa S., Tomonaga M., Geleziunas R., Yamamoto N. Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 99(4):2002;1341-1349.
39. Yoshida M. Multiple viral strategies of HTLV-I for dysregulation of cell growth control. Annual Review of Immunology. 19:2001;475-496.
40. Grant C., Barmak K., Alefantis T., Yao J., Jacobson S., Wigdahl B. Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. Journal of Cellular Physiology. 190(2):2002;133-159.